Search

Displaying results 2591 - 2600 of 3732 in total
  1. Drug

    Human placenta hydrolysate

    go.drugbank.com/drugs/DB19297
    Investigational

    Categories: Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 Enzyme Inhibitors
  2. Drug

    Benzgalantamine

    go.drugbank.com/drugs/DB19353
    ApprovedInvestigational

    Benzgalantamine is a prodrug of galantamine. Gastrointestinal adverse effects are the most frequently reported side effects in patients undergoing treatment with cholinesterase inhibitors, including galantamine, and are often a reason fo...

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates
  3. Drug

    Hydrastine

    go.drugbank.com/drugs/DB19354
    Experimental

    Categories: Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 Substrates
  4. Drug

    Setileuton

    go.drugbank.com/drugs/DB19550
    Investigational

    Setileuton is a small molecule drug. The usage of the INN stem '-leuton' in the name indicates that Setileuton is a 5-lipo-oxygenase inhibitor, anti-inflammatory. Setileuton is under investigation in clinical trial NCT00404313 (The Effec...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates
  5. Drug

    Mifentidine

    go.drugbank.com/drugs/DB19721
    Experimental

    The usage of the INN stem '-tidine' in the name indicates that Mifentidine is a histamine- H2​-receptor antagonist, cimetidine derivative. Mifentidine has a monoisotopic molecular weight of 228.14 Da.

    Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 Enzyme Inhibitors
  6. Drug

    Umbralisib

    go.drugbank.com/drugs/DB14989
    ApprovedInvestigationalWithdrawn

    Marginal zone lymphoma is a rare, slowly progressing type of non-Hodgkin lymphoma initially treated with rituximab (an anti-CD20 drug), either alone or in combination with chemotherapy. Unfortunately, many patients experience a relapse o...

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates
  7. Drug

    Brepocitinib

    go.drugbank.com/drugs/DB15003
    ApprovedInvestigational

    Brepocitinib is an oral Janus kinase (JAK) and tyrosine kinase 2 (TYK2) inhibitor used to treat dermatomyositis in adults. It inhibits TYK2- and JAK1-mediated cytokine signaling, blocking phosphorylation of signal transducers and activat...

    Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitors
  8. Drug

    Gefapixant

    go.drugbank.com/drugs/DB15097
    Approved

    [L48596] Gefapixant is a novel antagonist of the P2X3 receptor that works to reduce the cough reflex in patients with chronic cough.

    Categories: P-glycoprotein substrates
  9. Drug

    Vamorolone

    go.drugbank.com/drugs/DB15114
    ApprovedInvestigational

    [L48676] Vamorolone is positioned as having a more tolerable adverse effect profile than other corticosteroids owing to its unique receptor binding profile,[A261976] thus providing an additional treatment

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Inducers
  10. Drug

    Pozelimab

    go.drugbank.com/drugs/DB15218
    ApprovedInvestigational

    [A261120] Pozelimab is a human, monoclonal immunoglobulin G4<sup>P</sup> antibody against the terminal complement protein C5.